{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:28:50Z","timestamp":1780475330249,"version":"3.54.1"},"reference-count":24,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,11,22]]},"abstract":"<jats:p>Background: Donepezil is frequently used to treat Alzheimer\u2019s disease (AD) symptoms but is associated with early discontinuation. Determining the persistence rates of anti-dementia drug use after donepezil initiation may inform the development and improvement of treatment strategies, but there is little evidence from Japan. Objective: To determine anti-dementia drug persistence following donepezil initiation among AD patients in Japan using insurance claims data. Methods: Insurance claims data for AD patients with newly prescribed donepezil were obtained from 17 municipalities between April 2014 and October 2021. Anti-dementia drug persistence was defined as a gap of \u226460 days between the last donepezil prescription and a subsequent prescription of donepezil, another cholinesterase inhibitor, or memantine. Cox proportional hazards models were used to analyze the association between care needs levels and discontinuation. Results: We analyzed 20,474 AD patients (mean age\u00b1standard deviation: 82.2\u00b16.3 years, women: 65.7%). The persistence rates were 89.1% at 30 days, 79.4% at 90 days, 72.6% at 180 days, 64.5% at 360 days, and 58.3% at 540 days after initiation. Among the care needs levels, the hazard ratio (95% confidence interval) for discontinuation was 1.01 (0.94\u20131.07) for patients with support needs, 1.12 (1.06\u20131.18) for patients with low long-term care needs, and 1.31 (1.21\u20131.40) for patients with moderate-to-high long-term care needs relative to independent patients. Conclusion: Japanese AD patients demonstrated low anti-dementia drug persistence rates that were similar to those of other countries. Higher long-term care needs were associated with discontinuation. Further measures are needed to improve drug persistence in AD patients.<\/jats:p>","DOI":"10.3233\/jad-220200","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T11:28:14Z","timestamp":1664882894000},"page":"1177-1186","source":"Crossref","is-referenced-by-count":4,"title":["Anti-Dementia Drug Persistence Following Donepezil Initiation Among Alzheimer\u2019s Disease Patients in Japan: LIFE Study"],"prefix":"10.1177","volume":"90","author":[{"given":"Haruhisa","family":"Fukuda","sequence":"first","affiliation":[{"name":"Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Murata","sequence":"additional","affiliation":[{"name":"Omuta Hoyouin Hospital, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220200_ref1","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","journal-title":"Lancet Public Health"},{"key":"10.3233\/JAD-220200_ref2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer\u2019s disease facts and figures","volume":"12","author":"Alzheimer\u2019s Association","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220200_ref3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA approval of Aducanumab","volume":"385","author":"Alexander","year":"2021","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-220200_ref4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3988\/jcn.2021.17.3.376","article-title":"Discontinuation rate of newly prescribed donepezil in Alzheimer\u2019s disease patients in Asia","volume":"17","author":"Park","year":"2021","journal-title":"J Clin Neurol"},{"key":"10.3233\/JAD-220200_ref5","first-page":"1131","article-title":"Post-marketing surveillance of donepezil hydrochloride: Effectiveness, safety, and factors affecting persistence rates [in J apanese]","volume":"55","author":"Kitamura","year":"2017","journal-title":"Geriat Med"},{"key":"10.3233\/JAD-220200_ref6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JAD-190508","article-title":"One-year persistence with donepezil, memantine, and rivastigmine in more than 66,000 elderly patients followed in Poland","volume":"70","author":"Kostev","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220200_ref7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40266-017-0438-x","article-title":"Tolerability of cholinesterase inhibitors: A population-based study of persistence, adherence, and switching","volume":"34","author":"Fisher","year":"2017","journal-title":"Drugs Aging"},{"key":"10.3233\/JAD-220200_ref8","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jval.2016.03.1832","article-title":"Cholinesterase inhibitor utilization: The impact of provincial drug policy on discontinuation","volume":"19","author":"Fisher","year":"2016","journal-title":"Value Health"},{"key":"10.3233\/JAD-220200_ref9","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1532-5415.2007.01377.x","article-title":"A population-based study of cholinesterase inhibitor use for dementia","volume":"55","author":"Herrmann","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-220200_ref10","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00228-013-1483-y","article-title":"A population-based study of dosing and persistence with anti-dementia medications","volume":"69","author":"Brewer","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.3233\/JAD-220200_ref11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.18553\/jmcp.2008.14.5.451","article-title":"Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer\u2019s disease","volume":"14","author":"Mucha","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"10.3233\/JAD-220200_ref12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YIC.0000000000000032","article-title":"Antidementia drug use among community-dwelling individuals with Alzheimer\u2019s disease in Finland: A nationwide register-based study","volume":"29","author":"Taipale","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"10.3233\/JAD-220200_ref13","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1592\/phco.2005.25.12.1729","article-title":"Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition","volume":"25","author":"Kogut","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.3233\/JAD-220200_ref14","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/pds.1946","article-title":"Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer\u2019s disease","volume":"19","author":"Amuah","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.3233\/JAD-220200_ref15","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1017\/S1041610215000654","article-title":"Continuous treatment with antidementia drugs in Germany 2003-2013: A retrospective database analysis","volume":"27","author":"Bohlken","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-220200_ref16","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1017\/S1041610208007011","article-title":"Discontinuation of donepezil for the treatment of Alzheimer\u2019s disease in geriatric practice","volume":"20","author":"Umegaki","year":"2008","journal-title":"Int Psychogeriatr"},{"key":"10.3233\/JAD-220200_ref17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40263-013-0133-3","article-title":"A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer\u2019s disease in Europe: Predictors of discontinuation and switch in the ICTUS study","volume":"28","author":"Gardette","year":"2014","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-220200_ref18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.3233\/JAD-220200_ref19","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20210513"},{"key":"10.3233\/JAD-220200_ref20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000203887","article-title":"Long-term safety and efficacy of donepezil in patients with severe Alzheimer\u2019s disease: Results from a 52-week, open-label, multicenter, extension study in Japan","volume":"27","author":"Homma","year":"2009","journal-title":"Dement Geriatr CognDisord"},{"key":"10.3233\/JAD-220200_ref21","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/gps.1746","article-title":"Efficacy and safety of donepezil over 3 years: An open-label, multicentre study in patients with Alzheimer\u2019s disease","volume":"22","author":"Burns","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-220200_ref22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/gps.1133","article-title":"Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer\u2019s disease: A meta-analysis of individual patient data from randomised controlled trials","volume":"19","author":"Whitehead","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-220200_ref23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000122961","article-title":"Donepezil treatment of patients with severe Alzheimer\u2019s disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial","volume":"25","author":"Homma","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-220200_ref24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2377-11-57","article-title":"Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer\u2019s disease","volume":"11","author":"Farlow","year":"2011","journal-title":"BMC Neurol"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:07:44Z","timestamp":1777370864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":24,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-220200","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}